ONS ONCC Chemo Renewal

In the ever-evolving realm of oncology nursing, maintaining up-to-date knowledge and competencies is paramount. The Oncology Nursing Society (ONS) and the Oncology Nursing Certification Corporation (ONCC) have collaboratively designed the Chemotherapy Immunotherapy Certificate Renewal™ course to ensure that healthcare professionals remain adept in administering these critical treatments.

Understanding the ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal

The ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal™ course is tailored for nurses who have previously completed the initial certification. This renewal process is essential for those aiming to uphold their ONS Chemotherapy Immunotherapy Provider Card and the Certificate of Added Qualification (CAQ). The CAQ is valid for two years, necessitating timely renewal to ensure uninterrupted certification.

Eligibility and Renewal Process

To be eligible for renewal, nurses must ensure their provider card is current or within the 30-day grace period post-expiration. Registration for the renewal course is available on-demand, providing immediate access upon enrollment. It's imperative to note that if the provider card has expired beyond the 30-day grace period, nurses are required to retake the initial ONS/ONCC Chemotherapy Immunotherapy Certificate™ course to regain valid certification.

Renewal Deadlines and Fees

Adhering to renewal deadlines is crucial. The early-bird application deadline is September 15 of the year the certification expires, offering a $100 discount off the final deadline fee. The final application deadline is October 15. For those who miss these dates, a reinstatement application is available until March 31 of the following year, though additional fees may apply.

Utilizing Study Resources

To aid in preparation for the renewal process, various study resources are available. Platforms like Quizlet offer flashcards and study sets specifically designed for the ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal, providing an interactive way to review key concepts and terminologies.

The Imperative of Certification Renewal

Oncology nursing is a dynamic specialty, with continuous advancements in treatment protocols and patient care strategies. Maintaining certification through the ONS/ONCC renewal process ensures that nurses remain proficient in the latest chemotherapy and immunotherapy practices, ultimately enhancing patient outcomes. Moreover, certification renewal reflects a nurse's commitment to professional development and adherence to the highest standards of oncology care.

In conclusion, the ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal™ course is an indispensable component for oncology nurses dedicated to excellence in patient care. By staying current with certification requirements, nurses not only bolster their professional credentials but also contribute significantly to the advancement of oncology nursing practice.

Below are sample Questions and Answers:

50 - ANS-The chance of developing colorectal cancer increases markedly after age _____.
Roughly 9 out of 10 people diagnosed with colorectal cancer are at least ____ years old.
65 - ANS-The NCCN Older Adult Oncology Guidelines (version 1.2015) provides information on
what is included in a comprehensive geriatric assessment. Currently, more than 60% of cancers
in the United States occur in people age ______and older and as the oncology world ages,
nearly half (46%) of cancer survivors are 70 years of age or older
8.4% - ANS-It is important that the nurse recognizes certain drugs that, when given together,
may result in a higher risk of adverse events. For example, in neoadjuvant clinical trials using
trastuzumab and pertuzumab, the incidence of decline in left ventricular ejection fraction (LVEF)
was 1.9% in patients treated with trastuzumab and docetaxel, compared to ______ of those
treated with trastuzumab, docetaxel, and pertuzumab (Genentech, 2013).
85% - ANS-Amgen (2007) defines RDI as "is a quantification of how closely an administered
course of chemotherapy treatment adheres to a specific regimen." Three separate clinical trials
evaluating outcomes in patients with breast cancer related to RDI have demonstrated improved
overall survival and 10-year disease free survival in patients who receive a RDI > or =
____?_____
A comprehensive geriatric assessment (CGA) is a multidisciplinary evaluation to assess life
expectancy and risk of morbidity and mortality in the older patient. This assessment tool would
evaluate and include the following areas: functional status, socioeconomic issues, psychosocial
distress, comorbidities, cognitive function, nutritional status, polypharmacy, and a medication
review (NCCN Older Adult Oncology Guidelines, version 1.2015). - ANS-Due to Mrs. Turner's
age and comorbidities, her oncologist performs a comprehensive geriatric assessment. You
know that this assessment covers all but which of the following:
A dose-limiting toxicity of cyclophosphamide is hemorrhagic cystitis. Although it is more
commonly seen with high-dose therapy, it can still occur in patients receiving R-CHOP. -
ANS-Which of the agents that Mr. Rylan is receiving in R-CHOP would be the likely culprit if this
is hemorrhagic cystitis?
a. Stop the paclitaxel infusion - ANS-Mrs. Kearns is receiving her first dose of paclitaxel and
about 20 minutes into the infusion, you notice that she begins to start clearing her throat a lot.
She also states that she is having some lower back pain. You decide that you will take another
set of vital signs. While you are waiting for the monitor to reveal her blood pressure, she begins
to breathe heavier and appears short of breath.
What is the first/immediate thing you need to do for Mrs. Kearns?